Dissimilar Attenuation of Candida albicans Virulence Properties by Human Immunodeficiency Virus Type 1 Protease Inhibitors

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1983 • 52,849 citations

Active human immunodeficiency virus protease is required for viral infectivity.

1988 • 1,309 citations

Oral Candidiasis in High-Risk Patients as the Initial Manifestation of the Acquired Immunodeficiency Syndrome

1984 • 868 citations

HIV-Protease Inhibitors

1998 • 868 citations

L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor

1994 • 402 citations

Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

1988 • 327 citations

Recovery of the Immune System With Antiretroviral Therapy

1998 • 226 citations

Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors

1995 • 211 citations

INDUCIBLE PROTEINASE OF CANDIDA ALBICANS IN DIAGNOSTIC SEROLOGY AND IN THE PATHOGENESIS OF SYSTEMIC CANDIDOSIS

1980 • 200 citations

Oral candidiasis and human immunodeficiency virus infection

1989 • 199 citations

Evidence that Members of the Secretory Aspartyl Proteinase Gene Family, in ParticularSAP2,Are Virulence Factors forCandidaVaginitis

1999 • 173 citations

Candidiasis: Pathogenesis, Diagnosis and Treatment

1993 • 172 citations

The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages

1998 • 170 citations

Role of Protease Inhibitors in Preventing Recurrent Oral Candidosis in Patients With HIV Infection: A Prospective Case-Control Study

1999 • 136 citations

Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus

1996 • 123 citations

Candidiasis : pathogenesis, diagnosis, and treatment

1993 • 120 citations

Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: Implications for the design of antifungal agents

1996 • 110 citations

Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients

1995 • 106 citations

Flow cytometric assay for combined measurement of phagocytosis and intracellular killing of Candida albicans

1984 • 76 citations

Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro

1999 • 70 citations

Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants

1997 • 69 citations

Human Immunodeficiency Virus Type 1 gp160 and gp41 Binding to Candida albicans Selectively Enhances Candidal Virulence In Vitro

1998 • 64 citations

HIV protease inhibitors influence the prevalence of oral candidosis in HIV‐infected patients: a 2‐year study

1998 • 61 citations

Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy.

1998 • 34 citations

Fluorescence assay for the detection of adherent Candida yeasts to target cells in microtest plates

1995 • 24 citations

Human Immunodeficiency Virus Type 1 gp41 Binds toCandida albicansvia Complement C3‐like Regions

1997 • 21 citations